Literature DB >> 3104019

Immunological study of ovarian inhibin.

Y Hasegawa, K Miyamoto, M Fukuda, Y Takahashi, M Igarashi.   

Abstract

Antisera to purified porcine follicular fluid inhibin of 32 K protein (pFF 32 K inhibin) were raised in rabbits. Increasing doses of an antiserum with high titer could neutralize the maximal suppression of FSH secretion caused by 10 ng of pFF 32 K inhibin from rat anterior pituitary cells in culture. A radioimmunoassay was developed using the antiserum and 125I-labelled pFF 32 K inhibin. Specificity of the antiserum was examined by comparing immunological and biological potencies of various inhibin preparations. Cross-reactivity tests revealed that the antiserum almost recognizes rat ovarian inhibin preparations. The antiserum also recognizes purified bovine follicular fluid inhibin of 32 K protein (bFF 32 K inhibin), but with a cross-reactivity of approximately 20%. Cross-reactivity of human follicular fluid to the antiserum was less than 10%. The antiserum also recognizes inhibin forms of higher molecular weights, 100 K, 80 K, and 55 K proteins, which have previously been identified by gel filtration or SDS-PAGE of crude pFF inhibin preparations under protein-dissociation conditions, indicating that these inhibin forms have common or closely related immunodetermining sites.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3104019     DOI: 10.1507/endocrj1954.33.645

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  2 in total

1.  Sensitive radioimmunoassay of total thyroxine (T4) in horses using a simple extraction method.

Authors:  Siriwan Tangyuenyong; Yasuo Nambo; Kentaro Nagaoka; Tomomi Tanaka; Gen Watanabe
Journal:  J Vet Med Sci       Date:  2017-07-11       Impact factor: 1.267

2.  3-Amidinophenylalanine-derived matriptase inhibitors can modulate hepcidin production in vitro.

Authors:  Erzsébet Pászti-Gere; Gergely Szombath; Michael Gütschow; Torsten Steinmetzer; András Székács
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-28       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.